Work

KRAS mutation-driven O-GlcNAcylation of CLDN18.2 enhances the progression of pancreatic cancer and reduces the efficacy of CLDN18.2-targeted therapy

Year: 2026

Type: article

Source: Gut

DOI: 10.1136/gutjnl-2025-336277

Authors: Jing Liu, Xupeng Hou, Lin Li, Weiwei Bai, Tianxing Zhou, Moran Chen, Hu Yu, Hongxia Sun, Tingting Xu, Yifei Wang, Antao Chang, Yukuan Feng, Jun Yu, Chongbiao Huang, Yongjie Xie, Jihui Hao

Institutions: Shanghai Medical College of Fudan University, Fudan University, Tianjin Medical University Cancer Institute and Hospital, Fudan University Shanghai Cancer Center, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine, Chinese Academy of Sciences, Tianjin Medical University, Chinese Academy of Sciences, Institute of Chemistry, State Key Laboratory for Structural Chemistry of Unstable and Stable Species

Language: English

Topic: Pancreatic and Hepatic Oncology Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: National Natural Science Foundation of China, National Key Research and Development Program of China

Awards: G4507870477, G5392116810

OpenAlex ID: W7119686181

FWCI: 16.08

Cites: 37

Cited by: 6

Related to: